Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Lung Cancer

Free Subscription 01.06.2026 1 Am J Clin Oncol 2 Am J Clin Pathol 1 Ann Surg Oncol 4 Ann Thorac Surg 7 Anticancer Res 5 BMC Cancer 1 Br J Cancer 1 Cancer Epidemiol Biomarkers Prev 1 Cancer Res 1 Cancer Sci 1 Carcinogenesis 1 Chest 1 Clin Exp Metastasis 4 Clin Lung Cancer 2 Int J Radiat Oncol Biol Phys 1 J Cancer Res Clin Oncol 3 J Clin Oncol 1 J Natl Cancer Inst 1 J Thorac Cardiovasc Surg 1 Lancet 5 Lung Cancer 2 Oncol Rep 1 PLoS Med 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Clin Oncol

1. POWELL N, Hinojos M, Ayyalasomayajula S, Mikesell S, et al
   Comorbidity Burden, Treatment, and Survival Among Screen-Detected Lung Cancer Patients: Implications for USPSTF Guidelines.
   Am J Clin Oncol. 2026 May 15. doi: 10.1097/COC.0000000000001334.
   PubMed         Abstract available
   
   

   
   Am J Clin Pathol

2. MUJCIN M, Ferraro P, Verschelden P, Tran-Thanh D, et al
   Primary Paget-like intraepithelial glandular lesion of the bronchus: report of a first case.
   Am J Clin Pathol. 2026;165:aqag048.
   PubMed         Abstract available
   
   
3. BUTNOR KJ, Westcom AM
   Hilar fat invasion is a poorly defined and inconsistently interpreted lung carcinoma staging parameter.
   Am J Clin Pathol. 2026;165:aqag044.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

4. QI YF, Qiu ZB, Huang WY, Zhang C, et al
   The Role of PD-L1 in Treatment Decision-Making for Perioperative EGFR-Mutated Lung Cancer and its Genomic Analysis.
   Ann Surg Oncol. 2026 May 27. doi: 10.1245/s10434-026-19781.
   PubMed         Abstract available
   
   

   
   Ann Thorac Surg

5. POTTER AL, Wang D, Bonnell L, Jacobs RC, et al
   Comparing Nodal Upstaging Rates and Morbidity and Mortality of Common Nodal Sampling Guidelines in the STS General Thoracic Surgery Database.
   Ann Thorac Surg. 2026;121:1309-1317.
   PubMed         Abstract available
   
   
6. BAIU I, Altorki NK, Kneuertz PJ
   Wedge Resection for Early-Stage Non-Small Cell Lung Cancer: Are We There Yet?
   Ann Thorac Surg. 2026;121:1299-1308.
   PubMed         Abstract available
   
   
7. SERVAIS EL, Hayanga JWA, Linden P, Sood P, et al
   The Society of Thoracic Surgeons (2025) Expert Consensus Document on Interventions for Screen-Detected Lung Nodules.
   Ann Thorac Surg. 2026;121:1283-1297.
   PubMed         Abstract available
   
   
8. CATELLI C, Guerrini S, D'Alessandro M, Mazzei MA, et al
   Lymph Node Involvement and Radiological Predictors of Invasiveness in Pure Ground-Glass Adenocarcinomas: the GORDON study.
   Ann Thorac Surg. 2025 Nov 10:S0003-4975(25)01104.
   PubMed         Abstract available
   
   

   
   Anticancer Res

9. JU N, Hayashi H, Chang C, Nakagami H, et al
   A RANKL-derived Peptide Inhibits RSPO3-LGR4-Wnt Signaling and Lung Adenocarcinoma in Mice.
   Anticancer Res. 2026;46:3033-3045.
   PubMed         Abstract available
   
   
10. YAMADA Y, Matsumoto M, Ikehara M, Tsujino T, et al
    Clinical Features and Prognostic Significance of Pulmonary Metastases in Metastatic Hormone-sensitive Prostate Cancer.
    Anticancer Res. 2026;46:3461-3472.
    PubMed         Abstract available
    
    
11. TAKENAKA T, Tokunaga T, Kinoshita F, Iwamoto N, et al
    Comparison of RATS Lobectomy and VATS Lobectomy for Early-stage Non-small Cell Lung Cancer.
    Anticancer Res. 2026;46:3483-3491.
    PubMed         Abstract available
    
    
12. KIM N, Kim J, Nguyen HA, Mun SH, et al
    Silencing of beta-TrCP2 Suppresses Growth and G(1)/S Cell Cycle Progression in Non-small Cell Lung Carcinoma Cells.
    Anticancer Res. 2026;46:3131-3144.
    PubMed         Abstract available
    
    
13. YUN JH, Yoo S, Noh Y, Song J, et al
    Targeting AURKB Attenuates Tumor Growth in MYC-driven Lung Adenocarcinoma.
    Anticancer Res. 2026;46:3079-3090.
    PubMed         Abstract available
    
    
14. IKEGAMI K, Makihara RA, Shinno Y, Tateishi A, et al
    The Association Between Longitudinal Changes in TRACP-5b and Bone Metastasis Progression During Osimertinib Therapy.
    Anticancer Res. 2026;46:3373-3381.
    PubMed         Abstract available
    
    
15. TAKAHARA Y, Abe R, Nagae S, Tanaka T, et al
    Pretreatment Tumor Growth Rate and Clinical Outcomes in Advanced Non-small Cell Lung Cancer.
    Anticancer Res. 2026;46:3407-3415.
    PubMed         Abstract available
    
    

    
    BMC Cancer

16. LIN F, Xue J, Li Q, Tang W, et al
    Safety, pharmacokinetics, pharmacodynamics and antitumor activity of legubicin in patients with advanced solid tumors, including lung cancer: a phase 1 dose-escalation and expansion trial.
    BMC Cancer. 2026 May 29. doi: 10.1186/s12885-026-16261.
    PubMed         Abstract available
    
    
17. MENG J, Wu J, Li Q
    Correlation between preoperative T-cell receptor profile characteristics and postoperative pathological stage/treatment response in non-small cell lung cancer: a prospective cohort study.
    BMC Cancer. 2026 May 29. doi: 10.1186/s12885-026-16046.
    PubMed         Abstract available
    
    
18. FU YC, Xie SD, Guo XY, Li ZH, et al
    Checkpoint inhibitor pneumonitis in lung cancer patients receiving immune checkpoint inhibitors prior to chest radiotherapy.
    BMC Cancer. 2026 May 28. doi: 10.1186/s12885-026-16267.
    PubMed         Abstract available
    
    
19. YANG R, Liu X, Zuo F, Jimenez-Herrera MF, et al
    Perceived stigma among lung cancer patients: a cross-sectional study with latent profile analysis.
    BMC Cancer. 2026 May 26. doi: 10.1186/s12885-026-16253.
    PubMed         Abstract available
    
    
20. ZHENG S, Zuo Z, Lin R, Zhang X, et al
    The landscape of MET alterations in non-small cell lung cancer in Southeastern China: a real-world study.
    BMC Cancer. 2026 May 26. doi: 10.1186/s12885-026-16211.
    PubMed         Abstract available
    
    

    
    Br J Cancer

21. PARK SS, Lee HW, Kwon MR, Ju EJ, et al
    Silencing of NUP62 overcomes osimertinib resistance via ubiquitination of survivin in non-small cell lung cancer cells.
    Br J Cancer. 2026 May 26. doi: 10.1038/s41416-026-03475.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

22. MAO J, Leng L, Zhu T, Wang J, et al
    The association and risk prediction of the ubiquitination pathway genetic variants and lung cancer incidence: A nested case-control study.
    Cancer Epidemiol Biomarkers Prev. 2026.
    PubMed         Abstract available
    
    

    
    Cancer Res

23. YU J, Zhang J, Zhang J, Bai Z, et al
    MPND Loss Epigenetically Activates TGF-beta/SMAD3 Signaling to Drive Tumor Progression and Metastasis in Non-small Cell Lung Cancer.
    Cancer Res. 2026 May 27. doi: 10.1158/0008-5472.CAN-25-4336.
    PubMed         Abstract available
    
    

    
    Cancer Sci

24. KINOSHITA T, Ohta S, Wakui S, Maeda C, et al
    Tumor-Derived Extracellular Vesicles in Plasma for Predicting Anti-PD-1 Antibody Efficacy in Non-Small Cell Lung Cancer.
    Cancer Sci. 2026 May 24. doi: 10.1111/cas.70412.
    PubMed         Abstract available
    
    

    
    Carcinogenesis

25. 
    Retraction: ARHGAP24 inhibits cell proliferation and cell cycle progression and induces apoptosis of lung cancer via a STAT6-WWP2-p27 axis.
    Carcinogenesis. 2026;47:bgag028.
    PubMed        
    
    

    
    Chest

26. SONAWANE K, Garg A, Fox AH, Alexander M, et al
    State Variation in the Incidence of Small Cell Lung Cancer and its Association with Smoking.
    Chest. 2026 May 26:S0012-3692(26)00686-0. doi: 10.1016/j.chest.2026.
    PubMed        
    
    

    
    Clin Exp Metastasis

27. REYES JS, Bouras A, Hadjipanayis CG, Niranjan A, et al
    Local control and dose selection for lung cancer brain metastases treated with radiosurgery: an artificial intelligence model.
    Clin Exp Metastasis. 2026;43:27.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

28. ZAFAR M, Krishnakumar M, Dudiki N, Balguri S, et al
    Brief Report: Improving Lung Cancer Screening Rates: A Pilot Program for Low-Dose CT Implementation in a Community Cancer Center.
    Clin Lung Cancer. 2026;27:38-41.
    PubMed         Abstract available
    
    
29. UEHARA Y, Watanabe K, Tamura J, Ozawa Y, et al
    Predicting Radiation-Induced Esophagitis in Locally Advanced NSCLC Using Baseline Clinical Factors: A Model From the Japan Lung Cancer Society Integrated Phase II-III Database.
    Clin Lung Cancer. 2026 Apr 24:S1525-7304(26)00061.
    PubMed         Abstract available
    
    
30. NIE Y, Staley A, Hinz TK, Perez-Johnston R, et al
    High Programmed Death-Ligand 1 Expression is Associated With a Shorter Progression Free Survival in ALK-Rearranged Lung Cancer Patients Treated With First Line Tyrosine Kinase Inhibitors.
    Clin Lung Cancer. 2026 Apr 30:S1525-7304(26)00062.
    PubMed         Abstract available
    
    
31. ALIOUAT A, Chareire A, Bodergat T, Moncharmont C, et al
    Impact of Immune Checkpoint Inhibitor-Combined Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer With Brain Metastases.
    Clin Lung Cancer. 2026;27:42-47.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

32. LINGYUN W, Nakamura M, Toru M, Jing Y, et al
    Longitudinal Plasma Proteomics Reveals an Immuno-thrombotic Signature that Predicts Radiation Pneumonitis in Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2026 May 22:S0360-3016(26)00731.
    PubMed         Abstract available
    
    
33. SU T, Xu T, Chen M, Chen X, et al
    Long-term outcomes after proton therapy vs. intensity-modulated photon radiotherapy with concurrent chemotherapy for locally advanced non-small-cell lung cancer: post-hoc analysis of a prospective randomized trial.
    Int J Radiat Oncol Biol Phys. 2026 May 21:S0360-3016(26)00729.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

34. WANG X, Teng Y, Jiang M, Zhao X, et al
    Clinical significance of circulating FcgammaRIIa in the prognosis of patients with metastatic non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2026 May 24. doi: 10.1007/s00432-026-06505.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

35. HIDALGO-FILHO CM, Santo V, Gariazzo E, Aldea M, et al
    Overcoming Primary and Acquired Resistance to Immunotherapy in Non-Small Cell Lung Cancer: Mechanisms, Challenges, and Emerging Strategies.
    J Clin Oncol. 2026 May 22:JCO2503026. doi: 10.1200/JCO-25-03026.
    PubMed         Abstract available
    
    
36. BAZHENOVA L, Ismaila N, Durm G, Freeman-Daily J, et al
    Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.1.
    J Clin Oncol. 2026 May 26:JCO2600842. doi: 10.1200/JCO-26-00842.
    PubMed         Abstract available
    
    
37. REUSS JE, Ismaila N, Ahluwalia A, Campbell T, et al
    Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.1.
    J Clin Oncol. 2026 May 26:JCO2600843. doi: 10.1200/JCO-26-00843.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

38. BUTTIGIEG MM, Vlasschaert C, Pershad Y, Lanktree M, et al
    Air pollution modifies clonal hematopoiesis-associated non-small cell lung cancer risk in non-smoking individuals.
    J Natl Cancer Inst. 2026 May 27:djag159. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Thorac Cardiovasc Surg

39. LEE J, Han YB, Kim S, Kwon HJ, et al
    Differential prevalence and prognostic significance of spread through air spaces according to oncogenic driver mutations in lung adenocarcinoma.
    J Thorac Cardiovasc Surg. 2026;171:1320-1331.
    PubMed         Abstract available
    
    

    
    Lancet

40. XIONG A, Yao W, Zheng W, Yu Y, et al
    Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial.
    Lancet. 2026 May 29:S0140-6736(26)00968-2. doi: 10.1016/S0140-6736(26)00968.
    PubMed         Abstract available
    
    

    
    Lung Cancer

41. TASHKIN DP
    Lack of methodological clarity in the report of the association of cannabis use and lung cancer.
    Lung Cancer. 2026;217:109459.
    PubMed        
    
    
42. WANG Y, Liang S, Zhang JM, Sun ZH, et al
    Study on NGS-based molecular profiling of malignant pleural effusion supernatant cfDNA in guiding targeted therapy for non-small cell lung cancer.
    Lung Cancer. 2026;217:109463.
    PubMed         Abstract available
    
    
43. ADAR S, Adam A, Balogh T, Redei M, et al
    Sublobar resection, stereotactic body radiotherapy, and thermal ablation for early-stage non-small cell lung cancer: a systematic review and meta-analysis.
    Lung Cancer. 2026;217:109467.
    PubMed         Abstract available
    
    
44. BARLESI F, Skoulidis F, Solomon B, Lee J, et al
    First-line treatment patterns and real-world outcomes in patients with advanced KRAS-mutated non-small cell lung cancer with high unmet need.
    Lung Cancer. 2026;217:109471.
    PubMed         Abstract available
    
    
45. BUROTTO M, Zvirbule Z, Alvarez R, Chewaskulyong B, et al
    Efficacy and safety of subcutaneous and intravenous administration of atezolizumab in patients with non-small cell lung cancer, including early-stage, locally advanced or metastatic disease: Updated results of the IMscin001 and IMscin002 randomized st
    Lung Cancer. 2026;217:109452.
    PubMed         Abstract available
    
    

    
    Oncol Rep

46. GUO Z, Li X, Suo P, Lin Z, et al
    Targeting lung cancer with tanshinones: Current mechanistic evidence and emerging opportunities (Review).
    Oncol Rep. 2026;56:136.
    PubMed         Abstract available
    
    
47. QU F, Tong J, Qian W, He Q, et al
    Immune network remodeling driven by ferroptosis: Bidirectional interaction mechanisms among multiple immune cells in the lung cancer immune microenvironment (Review).
    Oncol Rep. 2026;56:135.
    PubMed         Abstract available
    
    

    
    PLoS Med

48. QI WX, Li S, Wang M, Li H, et al
    Sequential chemo-immunotherapy followed by standard versus reduced thoracic radiotherapy for older and/or frail stage III non-small-cell lung cancer: A randomized open-label cohort trial.
    PLoS Med. 2026;23:e1005111.
    PubMed         Abstract available
    
    

    
    PLoS One

49. PATASOVA K, Che WI, Westerlind H, Diaz-Gallo LM, et al
    Local genetic correlations between systemic sclerosis and common cancer types.
    PLoS One. 2026;21:e0350006.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum